Amgen (AMGN) revenue breakdown
By product, Product sales is the largest at 96% of fiscal 2025 revenue, growing 10% a year over 4 years.
By region, U.S. is the largest at 72% of fiscal 2025 revenue; ROW grew fastest, 9% a year over 9 years.
Revenue by product
Fiscal years, as Amgen reports them in its 10-K filings; fiscal 2025 total $36.8B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | — | — | — | — | $24.3B | $24.8B | $26.9B | $32.0B | $35.1B | 96% |
| Other revenues | $1.1B | $1.2B | $1.2B | $1.2B | $1.7B | $1.5B | $1.3B | $1.4B | $1.6B | 4% |
| Other products | $2.6B | $5.6B | $4.7B | $5.4B | — | — | — | — | — | — |
| Enbrel® (etanercept) | $5.4B | $5.0B | $5.2B | $5.0B | — | — | — | — | — | — |
| Prolia® (denosumab) | $2.0B | $2.3B | $2.7B | $2.8B | — | — | — | — | — | — |
| Neulasta® (pegfilgrastim) | $4.5B | $4.5B | $3.2B | $2.3B | — | — | — | — | — | — |
| Otezla | — | — | $178M | $2.2B | — | — | — | — | — | — |
| XGEVA® (denosumab) | $1.6B | $1.8B | $1.9B | $1.9B | — | — | — | — | — | — |
| Sensipar® / Mimpara® (cinacalcet) | $1.7B | — | — | — | — | — | — | — | — | — |
| Aranesp® (darbepoetin alfa) | $2.1B | $1.9B | $1.7B | $1.6B | — | — | — | — | — | — |
| EPOGEN® (epoetin alfa) | $1.1B | — | — | — | — | — | — | — | — | — |
| Kyprolis | $835M | $968M | $1.0B | $1.1B | — | — | — | — | — | — |
| Repatha (evolocumab) | — | $550M | $661M | $887M | — | — | — | — | — | — |
| Nplate | — | — | $795M | $850M | — | — | — | — | — | — |
| Evenity | — | — | — | $350M | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Amgen reports them in its 10-K filings; fiscal 2025 total $36.8B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. | $18.3B | $18.0B | $18.4B | $17.2B | $18.5B | $18.2B | $18.6B | $19.8B | $23.9B | $26.4B | 72% |
| ROW | $4.7B | $4.8B | $5.4B | $6.1B | $6.9B | $7.8B | $7.7B | $8.4B | $9.6B | $10.3B | 28% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AMGN.
Open AMGN in InvestinglyQuestions
Where does Amgen make its money?
In fiscal 2025, by product: Product sales $35.1B, Other revenues $1.6B.
From Amgen's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.